Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
about
Sipuleucel-T for metastatic castration-resistant prostate cancerChemotherapy for hormone-refractory prostate cancerShould docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contraNovel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancerEfficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsAdjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialAbiraterone in metastatic prostate cancer without previous chemotherapyThe role of RANK-ligand inhibition in cancer: the story of denosumabA 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapyOpen-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerCytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancerAndrogen deprivation therapy in the treatment of advanced prostate cancerA randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerA phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancerSipuleucel-T for metastatic castration-resistant prostate cancerMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerTaxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough StrategyAddition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerNon-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer MetabolismPersistent androgen receptor addiction in castration-resistant prostate cancerPrevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyInsights into Chemoresistance of Prostate CancerImmune Infiltration and Prostate CancerMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantImmunotherapy for prostate cancer: recent developments and future challengesPatient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision makingEmergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterialsEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Androgen receptor on the move: boarding the microtubule expressway to the nucleusCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesFrom bench to bedside: immunotherapy for prostate cancerCurrent clinical challenges in prostate cancerHealth Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
P2860
Q24186731-E5486C21-28EF-4BBC-A60A-B28D49C6D0A2Q24243797-F527A212-4145-4A2F-9D70-F6846FA3658DQ24289204-407831FB-CBCB-4DEF-9F01-CC4CC0305A0FQ24299807-ACD1F75E-B62D-4CFE-83C8-38B73F2EF963Q24599547-3BD009A3-2A62-45A4-9389-39E167EAF4EAQ24605205-D5A2F686-1E09-4565-A965-B56B8017FAFFQ24612084-3216FBE4-299D-4DCA-B3DB-A858474B261FQ24633284-B20B92EE-8671-4A6E-B1C0-2634182DE5D1Q24644493-F1F74DF5-174C-4AB8-906B-FE036301F6E4Q24647897-6A17B9F0-8884-4CA4-A530-6BABA3D1E98EQ24654354-EF35B714-74B6-46B0-9CD2-DE2B040F3BD8Q24676531-6AA93375-0E85-4830-A8E7-CB3857255471Q24684241-933BC246-3FC7-4BDF-9253-2D44B339B302Q25255692-1DB70EE8-8DE5-48A7-BBC6-3B528310DB40Q26471816-B9C343A3-F725-48C0-997B-90EC68C4B65EQ26739708-307D4F7D-D7DB-40E2-9C45-26D9B77603ACQ26747782-5F552609-FC28-4CB5-BD62-5EAB3A266817Q26752785-2338D327-8C99-4D96-9D77-7109B41E0A6EQ26770247-C1BB720F-D65B-4EDB-A574-0F1BF6E38164Q26771537-9F7C32AB-62D3-43E5-A85F-4BC69C7F05ABQ26772883-12A245B8-42A8-4893-AB5A-99FC25F009CCQ26773634-57F2038A-75CF-4C6B-B90C-11BC26A88E5CQ26774456-2E056FDF-3555-4FB5-8EB9-6E61A276B924Q26777163-23DAEAC7-20F8-405D-91B3-FF476AB87897Q26783861-DF3CE2FE-C3F1-4D14-A2D0-06AADE788555Q26786543-9339F626-77A9-444C-9707-56E44D70C5E3Q26795589-2680E630-9C8E-4688-AA03-A5CA9AD808B8Q26798412-77912993-A98D-4B62-AC0C-0DC04BAB6B0FQ26822406-D95033AB-5F4B-40D7-A83C-1DC1B0B7E830Q26825053-3442FA93-9E58-449E-B1B2-4760577EF6B2Q26851177-6980A31D-D77A-4533-88E4-C37C85EBCAD8Q26852388-A5BB4320-B995-4674-8D0C-0D0C05D5A54FQ26852751-87C9853D-ADD1-4608-B1D1-E5D8D3F83F74Q26860518-631E2A20-AA03-45C2-BF81-CB863356F4C8Q26861575-F52FF13F-145B-4B7E-BB1C-D205C404063CQ26862560-C9578AB4-8CEB-4FBF-86EA-4DACC1E52567Q26863779-BA4FE2A7-7F46-4A35-A5BC-5FBCEC369459Q26864390-A6C7DB42-D373-402E-AA8D-963C1534B913Q26866036-9171FDFA-7105-4242-AF58-D8E804F02715Q27004566-D35D0F20-95D2-4350-9136-87449733FB37
P2860
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Docetaxel and estramustine com ...... ced refractory prostate cancer
@ast
Docetaxel and estramustine com ...... ced refractory prostate cancer
@en
type
label
Docetaxel and estramustine com ...... ced refractory prostate cancer
@ast
Docetaxel and estramustine com ...... ced refractory prostate cancer
@en
prefLabel
Docetaxel and estramustine com ...... ced refractory prostate cancer
@ast
Docetaxel and estramustine com ...... ced refractory prostate cancer
@en
P2093
P3181
P356
P1476
Docetaxel and estramustine com ...... ced refractory prostate cancer
@en
P2093
Crawford ED
Hussain MH
Lara PN Jr
Moinpour C
Petrylak DP
P304
P3181
P356
10.1056/NEJMOA041318
P407
P577
2004-10-07T00:00:00Z